{'fraction_non_alphanumeric': 0.027777777777777776, 'fraction_numerical': 0.005555555555555556, 'mean_word_length': 5.380530973451328, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Selection of a genetically engineered biological drug for ankylosing spondylitis with extra-skeletal manifestations

Ankylosing spondylitis (AS) is a chronic, gradually progressive inflammatory disease of the spine, which in some patients can occur simultaneously with lesions of entheses and peripheral joints, and in some cases the eyes (uveitis) and the aortic root (aortitis). In more than 90% of cases, the genetic marker HLA-B27 is detected. This article presents a clinical case of ankylosing spondylitis in a man who received regular GEBD therapy, against the background of which uveitis recurred. After changing the drug, the inflammatory diseases of the eyes did not recur, and clinical remission was achieved.